Sihuan Pharmaceutical (00460.HK): The injectable polycaprolactone microsphere facial filler and the injectable sodium hyaluronate composite solution independently developed by Meiyan Space have been approved for marketing in Hong Kong.

Zhitong Finance APP News, Sihuan Pharmaceutical (00460.HK) announced that recently, the injectable polycaprolactone microsphere facial filler (PCL) and the injectable sodium hyaluronate composite solution (FL) (skin booster) independently developed and produced by Meiyan Space Biotechnology (Jilin) Co., Ltd. (Meiyan Space), a subsidiary of the Group, have successively been approved for marketing in the Hong Kong Special Administrative Region of China. The approved specifications of the injectable polycaprolactone microsphere facial filler include 0.5mL/vial, 1.0mL/vial, and 2.0mL/vial; the approved specifications of the injectable sodium hyaluronate composite solution include 0.5mL/vial, 1.0mL/vial, 1.5mL/vial, 2.0mL/vial, 2.5mL/vial, 3.0mL/vial, and 5mL/box (containing 2 units of 2.5mL/vial specification products).